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Method
Detection of anti-DRS-1 and anti-moesin autoantibodies by Western blotting analysis
Approximately 5 g of recombinant native DRS-1 or moesin protein per lane were electrophoresed in a 12% polyacrylamide gel and transferred to a PVDF membrane. The membrane was incubated in 3% BSA-PBS containing serum diluted 1:200 from this AA patient or a healthy individual (7, 8) .
Case report
A 15-month-old Japanese male was admitted to a nearby hospital due to a high fever and intraoral bleeding in February of 2006. He was born to healthy nonconsanguineous parents and was normally nourished. The family history did not include hematologic or malignant diseases. Physical examination on admission showed petechiae and no splenomegaly, and (Fig. 2) . A BM biopsy performed at 10 months of the first rituximab therapy showed myeloid and erythroid hyperplasia with reduced megakaryopoiesis (Fig. 1C) , and another BM biopsy performed at 22 months of the therapy revealed a hypercellularity of all three lineage of cells (Fig. 1D) . Abs against ssDNA, dsDNA, SS-A, SS-B, Sm, DRS-1 and moesin became undetectable in August of 2008 (Fig. 2) , and the titers of PA-IgG and anti-cardiolipin Abs were reduced from 142.9 to 71.1 ng/10 7 cells and from 39.1 to 17.9 U/mL, respectively. Some AA patients who failed to respond to ATG/CsA within 6 months of the therapy, conversely showed a late response and thereby eventually achieved transfusion-independence (18) . It therefore cannot be denied that the CR obtained after rituximab therapy was induced by ATG/CsA. However, our patient did not show any signs of hematologic improvement, such as an increase in the platelet or reticulocytes counts at the time of the rituximab 14 administration, which was day 168 of the ATG therapy. His neutrophil, reticulocyte and platelet count began to increase on day 50, day 158 and day 309 of the first rituximab therapy, respectively. Given the fact that it takes several weeks until the titer of pathogenic autoantibodies sufficiently decreases after rituximab administration, it seems more reasonable to ascribe the hematologic recovery to the effect of rituximab than to the late effect of ATG.
The disappearance of AA-associated autoantibodies including anti-DRS-1 Abs and anti-moesin Abs after rituximab supports the role of rituximab in the restoration of the patient's marrow failure.
In conclusion, we herein presented the first case where rituximab was successfully used as an alternative treatment for a pediatric patient with severe AA who was refractory to standard ATG/CsA therapy. The presence of autoantibodies such as anti-DRS-1 Abs and anti-moesin Abs may be useful for predicting response to rituximab therapy in AA patients.
The results of this case warrant a clinical trial using rituximab for the treatment of patients 15 with AA refractory to ATG. 
